News und Analysen

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their

For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

If you're in the process of rebalancing your portfolio, you might be considering buying Pfizer (NYSE: PFE) stock. After all, the drugmaker pays a sizzling 5.92% dividend yield, its shares trade at

If you're in the process of rebalancing your portfolio, you might be considering buying Pfizer (NYSE: PFE) stock. After all, the drugmaker pays a sizzling 5.92% dividend yield, its shares trade at

Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus

Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

Last year wasn't a particularly good one for Pfizer (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And

Last year wasn't a particularly good one for Pfizer (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

While investors love when one of their companies beats analyst estimates, it's not always the case that its stock rises in reaction. That was the case Friday with big health insurance company

While investors love when one of their companies beats analyst estimates, it's not always the case that its stock rises in reaction. That was the case Friday with big health insurance company

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q4 2023 Earnings CallJan 12, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q4 2023 Earnings CallJan 12, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com